Menu
23/04/2014
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay.
The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.1 months on similar treatments, and it is currently given to breast cancer patients who have failed on conventional treatment with Herceptin and chemotherapy.
The medicine, which is manufactured by Roche, will cost around £90,000 per patient.
Nice chief executive Sir Andrew Dillon said: "We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways than it will offer to patients with breast cancer."
Professor Paul Ellis, lead triallist for the drug in the UK and consultant oncologist at King's College. London said: "Kadcyla represents a significant advance in HER2-positive breast cancer, so for Nice to issue negative preliminary guidance is a huge blow.”
While Jayson Dallas, general manager of Roche Products Limited, said: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."
The decision is now up for public consultation and during this time patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.
(CVS)
The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.1 months on similar treatments, and it is currently given to breast cancer patients who have failed on conventional treatment with Herceptin and chemotherapy.
The medicine, which is manufactured by Roche, will cost around £90,000 per patient.
Nice chief executive Sir Andrew Dillon said: "We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways than it will offer to patients with breast cancer."
Professor Paul Ellis, lead triallist for the drug in the UK and consultant oncologist at King's College. London said: "Kadcyla represents a significant advance in HER2-positive breast cancer, so for Nice to issue negative preliminary guidance is a huge blow.”
While Jayson Dallas, general manager of Roche Products Limited, said: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."
The decision is now up for public consultation and during this time patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.
(CVS)
Related UK National News Stories
Click here for the latest headlines.
17 June 2005
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
13 June 2008
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
08 August 2011
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
30 September 2003
'Next big step' in breast cancer treatment launched
Cancer Research UK scientists will today embark on the next big step towards preventing breast cancer with the launch of a major new trial called IBIS II. The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease.
'Next big step' in breast cancer treatment launched
Cancer Research UK scientists will today embark on the next big step towards preventing breast cancer with the launch of a major new trial called IBIS II. The 10-year study will test a new drug called anastrozole and involve 10,000 healthy women who are at an increased risk of the disease.
24 May 2005
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
-
Northern Ireland WeatherThis Evening and Tonight:Showers gradually die out to leave good clear spells in the evening and overnight. This will allow a few fog patches to develop in places. A cold night with some ground frost. Minimum temperature 2 °C.
